Evidence map›Paper›PMID 38179146›Full record

ArticlePortal hypertension & cirrhosis2023

Comparison of patients with hepatitis B virus-associated hepatocellular carcinoma: Data from two hospitals from Turkey and China.

Brian I Carr, Fajuan Rui, Volkan Ince, Sezai Yilmaz, Xinya Zhao, Yuemin Feng, Jie Li

Abstract read
In one paragraph

Article in Portal hypertension & cirrhosis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Brian I CarrLiver Transplantation Institute, Inonu University, Malatya, Turkey.
Fajuan RuiDepartment of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Volkan InceLiver Transplantation Institute, Inonu University, Malatya, Turkey.
Sezai YilmazLiver Transplantation Institute, Inonu University, Malatya, Turkey.
Xinya ZhaoDepartment of Radiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China.
Yuemin FengDepartment of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China.
Jie LiDepartment of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.

Funding

K VITAMINS--A NEW CLASS OF LIVER CELL GROWTH INHIBITORSR01CA082723 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CARR, BRIAN I · 2000 to 2008
$2.3M
NCI NIH HHS R01 CA082723
6 · The paper itself

Abstract

Aims: There are many studies on the incidence of hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC), but very little is known about the HCC features in different populations. The study aimed to compare characteristics in two cohorts of patients with HBV-associated hepatocellular carcinoma, from Turkey and China. Methods: Data on patients with HBV-associated HCC diagnosed by imaging or liver biopsy were retrospectively collected from Shandong Provincial Hospital ( Results: The patients in the Turkish cohort had significantly worse Child-Pugh scores (Child-Pugh A: 38.3% vs. 87.9%; Child-Pugh B: 40.3% vs. 11.1%; Child-Pugh A: 24.1% vs. 1.0%; Conclusions: HBV-associated HCC from the Turkish cohort had worse liver function and more aggressive clinical characteristics than patients from the Chinese cohort.

Indexed as

ChinaHepatocellular CarcinomaTurkey

Identifiers

PMID38179146
PMCPMC10766430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.